GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GSK Pharmaceuticals reported standalone revenue of ₹3,79,020 lakhs for FY2026, up 1.8% from ₹3,72,349 lakhs in FY2025. Profit after tax grew 10.1% to ₹1,01,182 lakhs from ₹91,906 lakhs. The board recommended a higher dividend of ₹57 per share (vs ₹54 last year). EBITDA margin expanded from 33.4% to 36.2% on standalone basis. Operating cash flow remained healthy at ₹88,142 lakhs. The statutory auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional items of ₹264 lakhs came from sale of surplus residential properties. The company disclosed a ₹1,182 lakh impact from new Labour Codes on employee benefits expense.
Positive signals include margin expansion, dividend increase, and clean audit opinion. Revenue growth of under 2% is modest for the pharma sector. The stock should be viewed favorably given improving profitability and cash generation, though revenue growth remains sluggish.